Xspray and BMS settled the litigation for the Dasatinib outside of the court.
Case No 1:22-cv-00964-RMB-MJS2023 Plaintiff and Counter-Defendant: BRISTOL-MYERS SQUIBB CO., Defendant and Counter-Claimant: XSPRAY PHARMA AB Drug Product: Sprycel® Dasatinib Tablet (Applicant: BMS) Dasynoc® dasatinib (Applicant: Xspray ) Patent(s)-in-Suit: US7491725 (“the ’725 patent”), US8680103 (“the ’103 patent”), and US8242270 (“the ’270 patent”) FACTUAL AND PROCEDURAL BACKGROUND: · Bristol-Meyers Squibb (“BMS”) owns the patents-in-suit and sells Sprycel, a drug used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. · The patents-in-suit claim various crystalline forms of dasatinib. BMS asserts that Xspray filed an ANDA seeking to market a non-crystalline (i.e., amorphous) dasatinib product under the trade name Dasynoc. · BMS alleged that it received a ...